Cart
sales@molnova.com
Achyranthoside C
CAS No. 168009-90-3
Achyranthoside C( ——— )
Catalog No. M38817 CAS No. 168009-90-3
Achyranthoside C is a saponin from Achyranthes bidentata. The derivative of Achyranthoside C has inhibitory activity on osteoclast formation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 581 | Get Quote |
|
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAchyranthoside C
-
NoteResearch use only, not for human use.
-
Brief DescriptionAchyranthoside C is a saponin from Achyranthes bidentata. The derivative of Achyranthoside C has inhibitory activity on osteoclast formation.
-
DescriptionAchyranthoside C is a saponin from Achyranthes bidentata. The derivative of Achyranthoside C has inhibitory activity on osteoclast formation.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number168009-90-3
-
Formula Weight957.073
-
Molecular FormulaC47H72O20
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jian-Xin Li, et al. Five new oleanolic acid glycosides from Achyranthes bidentata with inhibitory activity on osteoclast formation. Planta Med. 2005 Jul;71(7):673-9.?
molnova catalog
related products
-
TC-N 1752
human NaV1.7 channels blocker.
-
CGGRGD
CGGRGD is a RGD derivative with cysteine as the n-terminal. CGGRGD was synthesized by solid phase peptide synthesis technology, and amino2-cyanobenzothiazole (2-cyanobenzothiazole) (2-cyanobenzothiazole (CBT) was added on the surface of PCL fiber for ammoniation.
-
PACMA 31
PACMA 31 is an irreversible and covalent inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. PACMA 31 significantly suppresses ovarian tumor growth and exhibits tumor targeting ability.
